INT24149

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1987
Last Reported 2009
Negated 0
Speculated 1
Reported most in Body
Documents 58
Total Number 87
Disease Relevance 93.54
Pain Relevance 2.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (BPHL) cellular amino acid metabolic process (BPHL)
Anatomy Link Frequency
nodules 10
stroma 1
lower urinary tract 1
Th17 cells 1
fibroblast 1
BPHL (Homo sapiens)
Pain Link Frequency Relevance Heat
Neurotransmitter 16 99.46 Very High Very High Very High
antagonist 439 97.78 Very High Very High Very High
Inflammation 186 97.52 Very High Very High Very High
cytokine 11 94.20 High High
Botox 112 94.16 High High
withdrawal 156 90.96 High High
Onset of action 57 89.52 High High
pain pelvic 1 88.48 High High
Prostatitis 9 87.68 High High
Central nervous system 29 87.52 High High
Disease Link Frequency Relevance Heat
Benign Prostatic Hypertrophy 7736 100.00 Very High Very High Very High
Overactive Bladder 1792 100.00 Very High Very High Very High
Lower Urinary Tract Symptoms 1708 100.00 Very High Very High Very High
Prostate Cancer 1643 100.00 Very High Very High Very High
Apoptosis 147 100.00 Very High Very High Very High
Prostatic Intraepithelial Neoplasia 14 100.00 Very High Very High Very High
Bacteremia 3 99.56 Very High Very High Very High
Urinary Tract Infection 153 99.46 Very High Very High Very High
Renal Insufficiency 82 98.68 Very High Very High Very High
Reprotox - General 1 736 98.46 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The PLESS and MTOPS trials, along with recent data on dutasteride, clearly show that therapy with a 5-alpha-reductase inhibitor decreases the risk of acute urinary retention and BPH-related surgery.3,4,40 These trials also confirm that BPH progression is related to baseline PSA, with values greater than 1.4–1.6 ng/mL leading to significantly greater risk of BPH-related events.3,4 Baseline prostate size has similar implications.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy and overactive bladder
1) Confidence 0.59 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.76 Pain Relevance 0.06
They have also proven to be beneficial in the prevention of BPH progression, as measured by prostate volume, the risk of developing acute urinary retention, and the risk of having BPH-related surgery.3 The use of an alpha-adrenergic receptor antagonist and a 5-alpha-reductase inhibitor as combination therapy seeks to provide symptomatic relief while preventing progression of BPH and has been validated by the Medical Therapy of Prostate Symptoms (MTOPS) trial.4 Anti-cholinergic agents and phosphodiesterase-5 inhibitors have also recently shown efficacy in the management of LUTS.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy, antagonist, overactive bladder and lower urinary tract symptoms
2) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.16 Pain Relevance 0.12
In the early 21st century, 5-alpha-reductase therapy is used to prevent progression of BPH, and is a viable alternative to alpha blockers or combination therapy for the treatment of symptoms.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
3) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.03 Pain Relevance 0.04
The investigators went further and evaluated whether any baseline parameter predicted BPH progression.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
4) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.18 Pain Relevance 0
In their analysis, an AUASS greater than 17 predicted BPH progression and increased rate of BPH-related therapy in all groups.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
5) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.14 Pain Relevance 0
Symptoms can be treated with alpha adrenergic receptor antagonists, long-term 5-alpha-reductase inhibitor therapy, or combination therapy whereas only 5-alpha-reductase inhibitors (as mono-therapy or part of combination therapy) seem to prevent progression of BPH.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy and antagonist
6) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.98 Pain Relevance 0.05
The most significant finding in the study, however, related to the progression of BPH.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
7) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.50 Pain Relevance 0
Dutasteride, because of dual inhibition of 5-alpha-reductase, results in a greater than 90% decrease in serum DHT levels.40 Three parallel, multicenter, randomized, placebo-controlled trials of 24 months’ duration have examined the safety and efficacy of dutasteride in men with BPH.40 All three studies included men 50 years or older with a clinical diagnosis of BPH, a transrectal ultrasonography (TRUS) prostate volume greater than 30mL, AUASS of 12 or more, and Qmax of 15 mL/sec or less.
Gene_expression (diagnosis) of BPH associated with benign prostatic hypertrophy
8) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.48 Pain Relevance 0
PSA greater than 1.6 ng/mL predicted symptom and overall BPH progression in the doxazosin group, acute urinary retention in all groups, and BPH-related therapy in the doxazosin and combination groups but not in the finasteride group.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy and overactive bladder
9) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.08 Pain Relevance 0
PSA greater than 1.6 ng/mL predicted symptom and overall BPH progression in the doxazosin group, acute urinary retention in all groups, and BPH-related therapy in the doxazosin and combination groups but not in the finasteride group.
Gene_expression (progression) of BPH-related associated with benign prostatic hypertrophy and overactive bladder
10) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.20 Pain Relevance 0
Two different goals of medical therapy are now apparent – treat the symptoms of BPH and prevent progression of BPH.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
11) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.86 Pain Relevance 0.05
These studies also confirmed the PLESS finding of decreased BPH progression in patients being treated with 5-alpha-reductase inhibitors.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
12) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.93 Pain Relevance 0
They have also proven to be beneficial in the prevention of BPH progression, as measured by prostate volume, the risk of developing acute urinary retention, and the risk of having BPH-related surgery.3 The use of an alpha-adrenergic receptor antagonist and a 5-alpha-reductase inhibitor as combination therapy seeks to provide symptomatic relief while preventing progression of BPH and has been validated by the Medical Therapy of Prostate Symptoms (MTOPS) trial.4 Anti-cholinergic agents and phosphodiesterase-5 inhibitors have also recently shown efficacy in the management of LUTS.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy, antagonist, overactive bladder and lower urinary tract symptoms
13) Confidence 0.51 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.30 Pain Relevance 0.13
Benign prostatic hypertrophy (BPH) produces symptoms that currently can only be treated surgically either by open or endoscopic prostatectomy.
Gene_expression (produces) of BPH associated with benign prostatic hypertrophy
14) Confidence 0.45 Published 1987 Journal Rofo Section Abstract Doc Link 2446357 Disease Relevance 0.35 Pain Relevance 0.07
-reductase reduces the clinical progression of BPH, an effect that is further enhanced by the addition of an ?
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
15) Confidence 0.33 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684085 Disease Relevance 1.08 Pain Relevance 0.07
-reductase inhibitor finasteride has been shown to significantly reduce the overall risk of clinical progression of BPH compared with the use of either drug alone.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
16) Confidence 0.33 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684085 Disease Relevance 0.92 Pain Relevance 0.05
Compared with the placebo group, the risk of clinical progression of BPH, reported as rate per 100 person-years, was reduced by 39% in the doxazocin group (p < 0.001), by 34% in the finasteride group (p = 0.002), and by 66% in the combination therapy group (p < 0.001).
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
17) Confidence 0.33 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684085 Disease Relevance 0.84 Pain Relevance 0.04
The primary outcome was clinical progression of BPH.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
18) Confidence 0.33 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684085 Disease Relevance 0.94 Pain Relevance 0.04
In conclusion, finasteride represents a cost-effective means of reducing BPH progression and its complications in men with enlarged prostates >30 cm3 while providing the additional benefits of decreased hematuria and prostate cancer rates.



Gene_expression (progression) of BPH associated with benign prostatic hypertrophy, reprotox - general 1 and hematuria
19) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710385 Disease Relevance 1.02 Pain Relevance 0
Therefore, the Medical Therapy of Prostatic Symptoms (MTOPS) Study was created to address the question of long-term benefit.34 Representing the longest and largest clinical trial conducted in patients with BPH, MTOPS evaluated whether finasteride combined with doxazosin was more effective than either placebo or monotherapy in prevention of clinical progression of BPH over a period of 4.5 years.
Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
20) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710385 Disease Relevance 0.55 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox